Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 1 Issue 11, November 2020

Volume 1 Issue 11

Bispecific nanobodies stabilize iNKT cell interactions for immunotherapy

VHH1D12 bispecific single-chain nanobodies stabilize interactions between invariant natural killer T cell receptors and MHC I–like CD1d molecules, which leads to enhanced anti-tumor immunity.

See Lameris et al. and the accompanying News & Views by Exley and Blumberg

Image: Erica Tandori, Monash University. Cover Design: Lauren Heslop.


  • Editorial |

    Nature Cancer encourages preprint sharing as a valuable means of research dissemination and scholarly communication.

Comment & Opinion

  • Comment |

    Recent advances in cancer neuroscience necessitate the systematic analysis of neural influences in cancer as potential therapeutic targets in oncology. Here we outline recommendations for future preclinical and translational research in this field.

    • Ihsan Ekin Demir
    • Carmen Mota Reyes
    • Brian M. Davis

News & Views

  • News & Views |

    Invariant natural killer T cells (iNKT cells) are innate-like CD1d-restricted T cells that have NK cell–like properties and bear an invariant T cell receptor (iTCR). iNKT cells have shown potential for cancer immunotherapy. A study now shows that stabilization of the iTCR–CD1d complex via a single-chain bi-specific antibody stimulates iNKT cell–mediated anti-tumor immunity.

    • Mark A. Exley
    • Thomas Gensollen
    • Richard S. Blumberg
  • News & Views |

    Tumor-specific changes in DNA methylation are both acquired actively through transcription-coupled processes and passively accumulated over time. Analysis across B cell malignancies now shows that these changes provide insight into the cellular origin as well as the proliferative history of tumors and thereby have diagnostic value and prognostic value, respectively.

    • Paolo Strati
    • Michael R. Green

Cancer in Translation

  • Cancer in Translation |

    Although RET alterations are relatively frequent across tumor types, specific targeting of RET in the clinic has been challenging. Ambrogio, Aggarwal and colleagues provide their views on how mechanistic studies have swiftly translated into powerful targeted therapies in two recent clinical studies that led to the FDA approval of selpercatinib for certain tumors in which RET is altered.

    • Melina E. Marmarelis
    • Roberto Chiarle
    • Charu Aggarwal



Amendments & Corrections


Quick links